Stock fact sheet · data as of
OptimizeRx Corp. (OPRX): fair value, margin of safety and Wheel Score
Healthcare · Medical - Healthcare Information Services · United States · High Growth
Is OPRX undervalued?
OPRX closed at 8.85 on 16 Oct 2026 against a GLS average fair value of 9.80 - 9.7% below fair value, which our screens read as "fairly priced". 2 of 7 models are above the current price. There is no discount to lean on here, so the margin of safety is not the reason to look at the stock.
There is a wide gap between Lynch (2.26) and 10 Cap (21.89). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files OPRX under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for OPRX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 6.20 | -30% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 6.46 | -27% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 2.26 | -74% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 8.72 | -2% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 21.89 | +147% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 20.35 | +130% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 2.72 | -69% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.8543 | -90% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 10.25 | +16% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
OptimizeRx Corp. scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 4.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC 3.3%, ROE 4.0%, ROA 2.9% - with debt at 0.20 times equity and a free-cash-flow yield of 11.0%.
OptimizeRx Corp. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Other Revenue 100% (fiscal year FY2025).
Institutional ownership scores 7/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 3.3% |
|---|---|---|---|
| GLS Moat | 4.7 / 10 | ROE | 4.0% |
| Debt / equity | 0.20 | ROA | 2.9% |
| Free-cash-flow yield | 11.0% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 62: Fair
A Wheel Score of 62 puts OptimizeRx Corp. in the Fair band - below the 70 the Sunday Scan requires. Value 17/25, Health 16/20, Moat 7/15, Premium 16/20 and Stability 7/20; the weakest part is Stability (7/20).
Implied volatility is 76% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (16 of 20) because volatility this high usually comes with a reason. Chain open interest is 2,790 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 148k shares a day on a market cap of $167M, with a beta of 1.09; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 17 / 25 | 10% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 7 / 15 | moat 4.7/10 | |
| Premium | 16 / 20 | implied volatility 76% | |
| Stability | 7 / 20 | 148k shares/day, $167M cap, beta 1.09 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026 (after the close), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Healthcare Information Services
The 12 companies below are the closest to OptimizeRx Corp. by market cap within the Medical - Healthcare Information Services industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| LFMDP LifeMD, Inc. | 22.41 | - | - | 24No options | $153M |
| HCAT Health Catalyst, Inc. | 1.80 | 4.95 | +64% | 45Weak | $135M |
| AMWL American Well Corporation | 12.38 | - | - | 38Weak | $211M |
| SPOK Spok Holdings, Inc. | 10.74 | 21.09 | +49% | 71Good | $224M |
| LFMD LifeMD, Inc. | 2.46 | - | - | 45Weak | $119M |
| DH Definitive Healthcare Corp. | 0.9961 | 5.68 | +82% | 45Weak | $106M |
| RVRC Revium Recovery Inc. | 1.43 | 0.0234 | -6006% | 10No options | $87M |
| SY So-Young International Inc. | 2.45 | - | - | 45Weak | $320M |
| CCLD CareCloud, Inc. | 1.93 | 4.23 | +54% | 53Fair | $82M |
| CARL Carlsmed, Inc. | 13.95 | 71.80 | +81% | 39No options | $381M |
| CTEV Claritev Corporation | 23.86 | 120.21 | +80% | 45Weak | $404M |
| NRC NRC Health | 21.11 | 8.64 | -144% | 47Weak | $467M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about OPRX
Is OPRX undervalued right now?
Not meaningfully: at 8.85 the stock trades within a few percent of the GLS average fair value of 9.80 (9.7% below fair value, data as of 16 Oct 2026).
What is the Wheel Score of OPRX and what does it mean?
OPRX scores 62 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for OPRX?
9.80 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does OptimizeRx Corp. report earnings next?
The next earnings report is due on 5 Nov 2026 (after the close), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does OPRX have listed options, and how liquid are they?
Yes. The nightly snapshot found 60 listed contracts with 2,790 open interest across all expiries and implied volatility of 76% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.